Solid Tumours Clinical Trials

78 clinical trials for Solid Tumours across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours — RECRUITING · PHASE1
• Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations — RECRUITING · PHASE2
• A Study of BI 3810944 in Patients With Advanced Cancer — RECRUITING · PHASE1
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab — RECRUITING · PHASE1
• A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors — RECRUITING · PHASE1
• A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours. — RECRUITING · PHASE1
• A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours — RECRUITING · PHASE1
• A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition — RECRUITING · PHASE2
• Tissue Collection Framework To Improve Outcomes In Solid Tumours — RECRUITING
• A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase 1 Trial of GEN1119 in Participants With Solid Tumors — NOT_YET_RECRUITING · PHASE1
• A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) — NOT_YET_RECRUITING · PHASE1
• A study to test how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumours) — NOT_YET_RECRUITING · PHASE1
• A Phase II, single-arm, open-label, long-term safety rollover trial of oral brigimadlin in patients with solid tumours — TERMINATED · PHASE2
• Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study — COMPLETED · NA
• A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test — COMPLETED
• Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis — COMPLETED
• An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumours — TERMINATED · PHASE2
• A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer) — NOT_YET_RECRUITING · PHASE2
• Phase I Trial of VS-6766 Alone and in Combination With Everolimus — COMPLETED · PHASE1
• A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) — OTHER · PHASE2
• A Study to Evaluate the Safety and Tolerability of EP0089 — NOT_YET_RECRUITING · PHASE1
• Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours — COMPLETED · PHASE1
• A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours — OTHER · PHASE1
• Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly — COMPLETED · PHASE1
• Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment — COMPLETED · PHASE1
• A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia — COMPLETED · PHASE1
• Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours — COMPLETED · PHASE1
• To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours — COMPLETED · PHASE1
• Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer — TERMINATED · PHASE1
• A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR — TERMINATED · PHASE1
• A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours — COMPLETED · PHASE3
• Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations — TERMINATED · PHASE1
• Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors — COMPLETED · PHASE2
• A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine — COMPLETED · PHASE1
• Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma — TERMINATED
• Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours — COMPLETED · PHASE1
• To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer — COMPLETED · PHASE1
• Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment — COMPLETED · PHASE1
• Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer — COMPLETED · PHASE1
• Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment — COMPLETED · PHASE1
• TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients — TERMINATED · PHASE1
• Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours — OTHER · PHASE1
• Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours — COMPLETED · PHASE1
• Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw — COMPLETED
• A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors — WITHDRAWN · PHASE2
• Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma — COMPLETED · PHASE1

Refine this search